Small molecule amyloid disrupters demonstrate therapeutic efficacy for transthyretin amyloidosis

08 April 2024, Version 1


The escalating global trend of an aging population has brought attention to the rising prevalence of late-onset amyloid disorders. Among them, transthyretin amyloidosis (ATTR) presents a growing medical challenge, particularly in the elderly. Herein we report the first therapeutic efficacy of a small molecule catalyst that selectively disrupts and neutralizes the intrinsic toxicity of aggregated transthyretin via photooxygenation. The established conditions demonstrated improved motility defect severity within the ATTR model C. elegans, the singularly acknowledged experimental modality recapitulating the clinical manifestation of ATTR. The approach was applicable to photooxygenation of cardiac amyloid fibrils extracted from an ATTR patient. In silico analysis provided a molecular rationale for the reactivity performance of the optimized catalyst, key to bridging the gap between in vivo applicability and therapeutic efficacy.


transthyretin amyloidosis
catalytic photooxygenation
small molecules
singlet oxygen


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.